Updated April 7, 2021 at 11:52 AM ET The European Union's drug regulator said Wednesday that the benefits of AstraZeneca's COVID-19 vaccine outweigh its risks, but that rare blood clotting events should be listed as a possible side effect. The European Medicines Agency's assessment comes after a panel of experts reviewed reports of unusual blood clots occurring in some vaccine recipients. Officials stressed these events are rare and said that while they appear to be more common in women under the age of 60, there is not enough available evidence to confirm specific risk factors such as age, gender or previous medical history. They said it is important for health care providers and the public to be aware of the signs and symptoms of these unusual events...
READ MORE >
EU Regulator: AstraZeneca Vaccine Effective; Blood Clots May Be A Rare Side Effect